Results 31 to 40 of about 263,171 (350)
European Psychiatry, 2021 Introduction The only FDA approval therapeutic for schizoaffective disorder is paliperidone. Hiperprolactinemia is one of the most frequent side effects induced by first generation antipsychotics (FGA) or by second generation antipsychotic (SGA), such ...
D. Rodrigues +3 more
doaj +1 more source
Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders
International Journal of Molecular Sciences, 2020 Atypical antipsychotic drugs were introduced in the early 1990s. Unlike typical antipsychotics, which are effective only against positive symptoms of schizophrenia, atypical antipsychotics are effective against negative and cognitive symptoms as well ...
D. Grinchii, E. Dremencov
semanticscholar +1 more source
Antipsychotics for irritability in children with Autism Spectrum Disorders
European Psychiatry, 2022 Introduction Autism is a neurodevelopmental disorder characterized by qualitative impairments in social interaction, communication, and restricted and repetitive behaviors [1]. Despite of these symptoms, some patients present different manifestations of
V. Muñoz Martinez +2 more
doaj +1 more source
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Biological Psychiatry, 2011 Background Schizophrenia is associated with immune system dysfunction, including aberrant cytokine levels. We performed a meta-analysis of these associations, considering effects of clinical status and antipsychotic treatment following an acute illness ...
B. Miller +4 more
semanticscholar +1 more source
Dosage of antipsychotics in China routine practice
European Psychiatry, 2021 Introduction The antipsychotic dosage of Chinese schizophrenia patients has rarely been studied, although nonstandard dosage has impact on prognosis. Objectives To describe the dosage of antipsychotics in China routine practice.
T. Zhang, R. Chi, T. Wu, Y. Xu, W. Dong
doaj +1 more source
JAMA psychiatry, 2019 Importance The effectiveness of antipsychotic polypharmacy in schizophrenia relapse prevention is controversial, and use of multiple agents is generally believed to impair physical well-being.
J. Tiihonen +5 more
semanticscholar +1 more source
Tobacco dependence and schizophrenia: Tunisian cross-sectional study of 50 cases
European Psychiatry, 2022 Introduction Tobacco-use is currently one of the major public health problems and is more common among patients with schizophrenia. Objectives We aimed in this study to estimate the prevalence of smoking in a population of patients with schizophrenia ...
M. Jabeur +5 more
doaj +1 more source
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness [PDF]
, 2018 BACKGROUND: There are conflicting data on the effects of antipsychotic medications on delirium in patients in the intensive care unit (ICU). METHODS: In a randomized, double-blind, placebo-controlled trial, we assigned patients with acute ...
Bernard, G.R. +31 more
core +1 more source
Journal of Market Access & Health Policy, 2017 Background: Adverse event (AE) reporting in clinical trials does not fully capture the patient-level perspective and comparing tolerability across treatments or among studies is difficult.
Clément François +8 more
doaj +1 more source
Treatment of early onset schizophrenia: Recent trends, challenges and future considerations
Frontiers in Psychiatry, 2012 Early onset schizophrenia (onset before adulthood) is a rare, severe and chronic form of schizophrenia. Antipsychotic treatment remains the mainstay of treatment although current medications provide suboptimal response at best.
Nora S Vyas, Nitin eGogtay
doaj +1 more source